Company news

Medipharm Labs Corp. (TSX:LABS) news

Medipharm Labs Corp. news releases on 6ix. Latest, Aug 13, 2026: MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive…

Medipharm Labs Corp. (TSX:LABS) news

Press releases & updates

MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA

MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results

MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia

MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders

MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results

MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience

MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns

MediPharm Labs Completes First Shipment to France

MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law

MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains

MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results

MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis

MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States

MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results

MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler

MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders

MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting

Apollo Capital Wins Proxy Contest at MediPharm Labs

Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees

MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline

MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting

Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World's Leading International Medical Cannabis Company

MediPharm Labs' Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident

MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility

Leading Independent Proxy Advisor ISS Recommends that Shareholders&#xA0;Vote the GREEN proxy FOR ALL MediPharm Director Nominees;&#xA0;REJECTS Apollo's Arguments and Director Slate

Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate

MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital

MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder

Alleged Securities Fraud at MediPharm Labs Says Apollo Capital

MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan

Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck's Past as CEO and VP of Marketing for OxyContin&#xAE; Manufacturer Purdue Pharma

MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement

MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.

MediPharm Labs Cautions Shareholders about Dissident Nominees' Governance Failures at Check-Cap Ltd.

Apollo Capital Comments on MediPharm Labs' Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting

MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June

Apollo Capital Issues a With Prejudice Offer to MediPharm Labs and Its Board of Directors to Ensure Shareholder Rights Are Protected at the 2025 Annual Meeting

MediPharm Labs Alerts Shareholders to Allegations&#xA0;Made Against Regan McGee in Multiple Litigation Filings

COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of Transparency Under Current Leadership

Apollo Capital Warns MediPharm Shareholders of Continued Value Destruction and Insolvency Risk Following Disastrous Q1 Financial Results

/U P D A T E -- MediPharm Labs Corp./

MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees

Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director Slate

Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck's Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma

MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings